{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:16:34Z","timestamp":1789143394455,"version":"build-2803163510"},"reference-count":31,"publisher":"Spandidos Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Ther Med"],"DOI":"10.3892\/etm.2023.12023","type":"journal-article","created":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T11:46:46Z","timestamp":1684237606000},"source":"Crossref","is-referenced-by-count":3,"title":["Complete remission of reactive cutaneous capillary endothelial proliferation caused by the programmed cell death-1 inhibitor camrelizumab achieved through thalidomide monotherapy: A case report"],"prefix":"10.3892","volume":"26","author":[{"given":"Chunxiu","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Oncology, The Second People's Hospital of Yibin, Yibin, Sichuan 644000, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaijian","family":"Lei","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second People's Hospital of Yibin, Yibin, Sichuan 644000, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuming","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second People's Hospital of Yibin, Yibin, Sichuan 644000, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuxin","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, The Second People's Hospital of Yibin, Yibin, Sichuan 644000, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanbing","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second People's Hospital of Yibin, Yibin, Sichuan 644000, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2023,5,16]]},"reference":[{"key":"key20230710064440_b1-ETM-26-1-12023","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/S1470-2045(18)30495-9","article-title":"Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: Results from two single-arm, phase 1 trials","volume":"19","author":"Fang","year":"2018","journal-title":"Lancet Oncol"},{"key":"key20230710064440_b2-ETM-26-1-12023","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/s41416-018-0100-3","article-title":"Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: A dose-escalation, phase 1 study","volume":"119","author":"Mo","year":"2018","journal-title":"Br J Cancer"},{"key":"key20230710064440_b3-ETM-26-1-12023","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1080\/0284186X.2019.1567935","article-title":"Reactive capillary hemangiomas induced by camrelizumab (SHR-1210), an anti-PD-1 agent","volume":"58","author":"Teng","year":"2019","journal-title":"Acta Oncol"},{"key":"key20230710064440_b4-ETM-26-1-12023","doi-asserted-by":"publisher","first-page":"173","DOI":"10.20892\/j.issn.2095-3941.2018.0172","article-title":"Reactive capillary hemangiomas: A novel dermatologic toxicity following anti-PD-1 treatment with SHR-1210","volume":"16","author":"Chen","year":"2019","journal-title":"Cancer Biol Med"},{"key":"key20230710064440_b5-ETM-26-1-12023"},{"key":"key20230710064440_b6-ETM-26-1-12023","doi-asserted-by":"publisher","first-page":"918","DOI":"10.3928\/23258160-20181203-02","article-title":"Quantitative vascular density changes in choriocapillaris around CNV after anti-VEGF treatment: Dark halo","volume":"49","author":"Rispoli","year":"2018","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"key20230710064440_b7-ETM-26-1-12023","doi-asserted-by":"publisher","first-page":"5334","DOI":"10.1200\/JCO.2005.03.723","article-title":"Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma","volume":"23","author":"Vacca","year":"2005","journal-title":"J Clin Oncol"},{"key":"key20230710064440_b8-ETM-26-1-12023","doi-asserted-by":"publisher","first-page":"22382","DOI":"10.1074\/jbc.M100938200","article-title":"Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity","volume":"276","author":"Keifer","year":"2001","journal-title":"J Biol Chem"},{"key":"key20230710064440_b9-ETM-26-1-12023","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.biocel.2007.01.022","article-title":"The thalidomide saga","volume":"39","author":"Melchert","year":"2007","journal-title":"Int J Biochem Cell Biol"},{"key":"key20230710064440_b10-ETM-26-1-12023","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1097\/00001622-200211000-00008","article-title":"Thalidomide and immunomodulatory drugs as cancer therapy","volume":"14","author":"Raje","year":"2002","journal-title":"Curr Opin Oncol"},{"key":"key20230710064440_b11-ETM-26-1-12023","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.ccr.2014.03.010","article-title":"A long noncoding RNA activated by TGF-\u03b2 promotes the invasion-metastasis cascade in hepatocellular carcinoma","volume":"25","author":"Yuan","year":"2014","journal-title":"Cancer Cell"},{"key":"key20230710064440_b12-ETM-26-1-12023","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/ajd.13812","article-title":"Thalidomide for prevention of camrelizumab-induced reactive cutaneous capillary endothelial proliferation","volume":"63","author":"Song","year":"2022","journal-title":"Australas J Dermatol"},{"key":"key20230710064440_b13-ETM-26-1-12023","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jconrel.2021.08.020","article-title":"Platelet-armored nanoplatform to harmonize janus-faced IFN-\u03b3 against tumor recurrence and metastasis","volume":"338","author":"Li","year":"2021","journal-title":"J Control Release"},{"key":"key20230710064440_b14-ETM-26-1-12023","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1039\/d1nh00506e","article-title":"A self-amplifying nanodrug to manipulate the Janus-faced nature of ferroptosis for tumor therapy","volume":"7","author":"Zhang","year":"2022","journal-title":"Nanoscale Horiz"},{"key":"key20230710064440_b15-ETM-26-1-12023","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/15569527.2022.2034842","article-title":"Adverse cutaneous toxicities by PD-1\/PD-L1 immune checkpoint inhibitors: Pathogenesis, treatment, and surveillance","volume":"41","author":"Bhardwaj","year":"2022","journal-title":"Cutan Ocul Toxicol"},{"key":"key20230710064440_b16-ETM-26-1-12023","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S1470-2045(20)30011-5","article-title":"Camrelizumab in patients with previously treated advanced hepatocellular carcinoma:A multicentre,open-label, parallel-group, randomised, phase 2 trial","volume":"21","author":"Qin","year":"2020","journal-title":"Lancet Oncol"},{"key":"key20230710064440_b17-ETM-26-1-12023","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer(KEYNOT-042):A randomised, open-label, controlled, phase 3 trail","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"key20230710064440_b18-ETM-26-1-12023","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.tranon.2019.02.007","article-title":"A phase Ib study of Pembrolizumab as second-line therapy for Chinese patients with advanced or metastatic melanoma(KEYNOTE-151)","volume":"12","author":"Si","year":"2019","journal-title":"Transl Oncol"},{"key":"key20230710064440_b19-ETM-26-1-12023","doi-asserted-by":"publisher","first-page":"7363","DOI":"10.1158\/1078-0432.CCR-19-1680","article-title":"A single-arm, multicenter, phase II study of camrelizumab in relapsed or refractory classical hodgkin lymphoma","volume":"25","author":"Song","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"47","key":"key20230710064440_b20-ETM-26-1-12023","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00886-2","article-title":"Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab:data derived from a multicenter phase 2 trial","volume":"13","author":"Wang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"key20230710064440_b21-ETM-26-1-12023","doi-asserted-by":"publisher","first-page":"624","DOI":"10.12998\/wjcc.v8.i3.624","article-title":"Camrelizumab (SHR-1210) leading to reactive capillary hemangioma in the gingiva:A case report","volume":"8","author":"Yu","year":"2020","journal-title":"World J Clin Cases"},{"key":"key20230710064440_b22-ETM-26-1-12023","first-page":"840","article-title":"Camrelizumab induced cutaneous capillary endothelial proliferation Clinical expert consensus","volume":"25","author":"Qin","year":"2020","journal-title":"Chin Clin Oncol"},{"key":"key20230710064440_b23-ETM-26-1-12023","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/S1470-2045(20)30110-8","article-title":"Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (Escort):A multicentre, randomised, open-label, phase 3 study","volume":"21","author":"Huang","year":"2020","journal-title":"Lancet Oncol"},{"key":"key20230710064440_b24-ETM-26-1-12023","doi-asserted-by":"publisher","first-page":"e536","DOI":"10.1634\/theoncologist.2019-0550","article-title":"Association between skin reaction and clinical benefit in patients treated with anti-programmed cell death 1 monotherapy for advanced non-small cell lung cancer","volume":"25","author":"Aso","year":"2022","journal-title":"Oncologist"},{"key":"key20230710064440_b25-ETM-26-1-12023","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.2217\/fon.10.75","article-title":"Ramucirumab (IMC-1121B):A novel attack on angiogenesis","volume":"6","author":"Spratlin","year":"2010","journal-title":"Future Oncol"},{"key":"key20230710064440_b26-ETM-26-1-12023","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1007\/s10637-017-0463-y","article-title":"Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors","volume":"35","author":"Lee","year":"2017","journal-title":"Invest New Drugs"},{"key":"key20230710064440_b27-ETM-26-1-12023","doi-asserted-by":"publisher","first-page":"7113","DOI":"10.1158\/1078-0432.CCR-07-1550","article-title":"Phase I evaluation of CDP791, a pegylated di-Fab' conjugate that binds vascular endothelial growth factor receptor2","volume":"13","author":"Ton","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"9112","key":"key20230710064440_b28-ETM-26-1-12023","article-title":"Efficacy of PD-1 monoclonal antibody SHR-1210 plus Apatinib in patients with advanced non-squamous NSCLC with wild-type EGFR and ALK","volume":"35","author":"Zhou","year":"2019","journal-title":"J Clin Oncol"},{"key":"key20230710064440_b29-ETM-26-1-12023","doi-asserted-by":"publisher","first-page":"3055","DOI":"10.22034\/APJCP.2017.18.11.3055","article-title":"Anti-vascular endothelial growth factor targeting by curcumin and thalidomide in acute myeloid leukemia cells","volume":"18","author":"Salemi","year":"2017","journal-title":"Asian Pac J Cancer Prev"},{"key":"key20230710064440_b30-ETM-26-1-12023","doi-asserted-by":"publisher","first-page":"192","DOI":"10.2174\/187221411797265890","article-title":"Immunomodulatory Properties of Thalidomide Analogs: Pomalidomide and lenalidomide, experimental and therapeutic applications","volume":"5","author":"Bodera","year":"2011","journal-title":"Recent Pat Endocr Metab Immune Drug Discov"},{"key":"key20230710064440_b31-ETM-26-1-12023","first-page":"1253","article-title":"Effects of Thalidomide on the Expression of Collagen IA1 and Regulatory Factor in Histamine-activated Human Dermal Fibroblasts","volume":"36","author":"Bai","year":"2022","journal-title":"Chin J Derm Venereol"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"deposited":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T06:44:55Z","timestamp":1688971495000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/etm.2023.12023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,16]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,5,16]]}},"URL":"https:\/\/doi.org\/10.3892\/etm.2023.12023","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,16]]},"article-number":"324"}}